Innovative Diagnostic Solutions NephroSant has developed a reliable, low-cost, and non-invasive assay to detect kidney injury and transplant rejection, presenting a significant opportunity for healthcare providers seeking better diagnostic tools in nephrology and transplant management.
Funding and Market Readiness With over $22 million in funding and a recent Series A of $16 million, NephroSant is financially positioned to accelerate its commercialization efforts, making it an attractive partner for sales teams targeting early adopters in transplant centers and nephrology clinics.
Strategic Hiring & Leadership The appointment of a chief commercialization officer indicates a focused push towards market entry and expansion, providing opportunities to connect with key decision-makers involved in transplant protocols and laboratory diagnostics.
Technology Ecosystem Utilizing cloud services like AWS, Salesforce, and development tools such as GitHub and Docker, NephroSant demonstrates a strong technical infrastructure, facilitating scalable implementation and integration with hospital information systems.
Market Expansion Potential Positioned within biotechnology research and targeting transplantation monitoring, NephroSant’s products address a high-need area with growing demand, offering sales opportunities within academic, clinical, and commercial healthcare markets worldwide.
Nephrosant, Inc. uses 8 technology products and services including Varnish, Amazon EC2, Angular, and more. Explore Nephrosant, Inc.'s tech stack below.
| Nephrosant, Inc. Email Formats | Percentage |
| FLast@nephrosant.com | 39% |
| Last@nephrosant.com | 19% |
| First@nephrosant.com | 3% |
| FLast@nephrosant.com | 39% |
Biotechnology ResearchCalifornia, United States2-10 Employees
Kidney transplantation is the treatment of choice for patients with end-stage kidney failure. However, the life of a kidney transplant is limited due to unrecognized immune injury. There is no sensitive, non-invasive method to detect this injury at an early-stage. We have developed a reliable, inexpensive, and noninvasive assay to monitor kidney injury.
Company Overview
Funding & FinancialsNephrosant, Inc. has raised a total of $16M of funding over 1 rounds. Their latest funding round was raised on Mar 16, 2021 in the amount of $16M.
Nephrosant, Inc.'s revenue is estimated to be in the range of $1M
Funding & FinancialsNephrosant, Inc. has raised a total of $16M of funding over 1 rounds. Their latest funding round was raised on Mar 16, 2021 in the amount of $16M.
Nephrosant, Inc.'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com